Silodosin

Entry

D01965                      Drug

Name

Silodosin (JP18/INN);
KMD 3213;
Rapaflo (TN);
Urief (TN)

Product

RAPAFLO (Allergan)

Generic

SILODOSIN (Ajanta Pharma USA), SILODOSIN (Alembic Pharmaceuticals), SILODOSIN (Alembic Pharmaceuticals Limited), SILODOSIN (Amneal Pharmaceuticals NY LLC), SILODOSIN (Amneal Pharmaceuticals NY LLC), SILODOSIN (Aurobindo Pharma Limited), SILODOSIN (Camber Pharmaceuticals), SILODOSIN (Lupin Pharmaceuticals), SILODOSIN (MSN LABORATORIES PRIVATE LIMITED), SILODOSIN (Macleods Pharmaceuticals Limited), SILODOSIN (Novadoz Pharmaceuticals LLC), SILODOSIN (PD-Rx Pharmaceuticals), SILODOSIN (Sandoz)

Formula

C25H32F3N3O4

Exact mass

495.2345

Mol weight

495.5345

Structure

Class

Cardiovascular agent
DG01466  Adrenergic receptor antagonist
  DG01465  alpha-Adrenergic receptor antagonist
   DG01457  alpha1-Adrenergic receptor antagonist
Metabolizing enzyme substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
DG02924  UGT substrate

Remark

Therapeutic category:

2590

ATC code:

G04CA04

Product:

D01965<JP/US>

Efficacy

Antidysuria, alpha1-Adrenergic receptor antagonist

Target

ADRA1A [HSA:148] [KO:K04135]

Pathway

hsa04022

cGMP-PKG signaling pathway

hsa04080

Neuroactive ligand-receptor interaction

hsa04270

Vascular smooth muscle contraction

Metabolism

Enzyme: CYP3A4 [HSA:1576], UGT [KO:K00699]

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
  G04 UROLOGICALS
   G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
    G04CA Alpha-adrenoreceptor antagonists
     G04CA04 Silodosin
      D01965  Silodosin (JP18/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
  Benign Prostatic Hypertrophy Agents
   Silodosin
    D01965  Silodosin (JP18/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  25  Urogenital and anal organ agents
   259  Miscellaneous
    2590  Miscellaneous
     D01965  Silodosin (JP18/INN)
Drug groups [BR:br08330]
Cardiovascular agent
  DG01466  Adrenergic receptor antagonist
   DG01465  alpha-Adrenergic receptor antagonist
    DG01457  alpha1-Adrenergic receptor antagonist
     D01965  Silodosin
Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D01965  Silodosin
  DG02924  UGT substrate
   D01965  Silodosin
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
  Rhodopsin family
   Adrenaline
    ADRA1A
     D01965  Silodosin (JP18/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
  D01965  Silodosin
  D01965  Silodosin tablets
  D01965  Silodosin orally disintegrating tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D01965
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D01965
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D01965
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D01965
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D01965

Other DBs

CAS:	160970-54-7

PubChem:

7849027

LigandBox:

D01965

KCF data

ATOM        35
            1   C8y C    25.3627  -16.7293
            2   C8x C    25.3627  -18.1293
            3   C8y C    26.5750  -18.8293
            4   C8y C    27.7875  -18.1293
            5   C8y C    27.7875  -16.7293
            6   C8x C    26.5750  -16.0294
            7   N1y N    29.1189  -18.5619
            8   C1x C    29.9418  -17.4293
            9   C1x C    29.1189  -16.2967
            10  C1b C    29.5453  -19.8751
            11  C1b C    30.9269  -20.1692
            12  C1b C    31.3587  -21.4994
            13  O1a O    32.7377  -21.7931
            14  C5a C    26.5750  -20.2312
            15  N1a N    25.3646  -20.9301
            16  O5a O    27.7896  -20.9325
            17  C1b C    24.1519  -16.0310
            18  C1c C    22.9393  -16.7310
            19  N1b N    21.7269  -16.0310
            20  C1b C    20.5143  -16.7310
            21  C1b C    19.3018  -16.0310
            22  O2a O    18.0893  -16.7310
            23  C8y C    16.8768  -16.0310
            24  C1a C    22.9375  -18.1311
            25  C8y C    16.8768  -14.6309
            26  C8x C    15.6643  -13.9309
            27  C8x C    14.4518  -14.6309
            28  C8x C    14.4518  -16.0310
            29  C8x C    15.6643  -16.7310
            30  O2a O    18.0846  -13.9336
            31  C1b C    19.2952  -14.6325
            32  C1d C    20.5100  -13.9312
            33  X   F    20.5106  -12.5306
            34  X   F    21.7226  -14.6316
            35  X   F    21.7240  -13.2307
BOND        37
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    5   9 1
            11    7  10 1
            12   10  11 1
            13   11  12 1
            14   12  13 1
            15    3  14 1
            16   14  15 1
            17   14  16 2
            18    1  17 1
            19   17  18 1
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   18  24 1 #Up
            26   23  25 2
            27   25  26 1
            28   26  27 2
            29   27  28 1
            30   28  29 2
            31   23  29 1
            32   25  30 1
            33   30  31 1
            34   31  32 1
            35   32  33 1
            36   32  34 1
            37   32  35 1